Supported by state-of-the-art systems medicine competences including integrative computational and functional genomics, the overarching goal of the trial is to investigate the impact of qualitative and quantitative changes in the gut microbiota on the pathogenesis of cardiometabolic diseases (CMDs) and their associated co-morbidities. A major objective will be to translate the clinical and fundamental based discoveries into new diagnosis and preventive actions paving the way to novel modes of treatment in the successive stages of CMD progression.

开始日期2013-06-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

100 项与 Liver(Esperion Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Liver(Esperion Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Liver(Esperion Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 Liver(Esperion Therapeutics) 相关的文献（医药）

2021-09-01·Molecular Biology Reports4区 · 生物学

Prophylactic effect of myricetin and apigenin against lipopolysaccharide-induced acute liver injury

4区 · 生物学

Article

作者: Aslan, Ali ; Ünal, Seda ; Özlüer-Hunt, Arzu ; Yunusoğlu, Oruç ; Özkan-Yılmaz, Ferbal ; Berköz, Mehmet ; Karayakar, Fahri

BACKGROUNDLiver has an important role in the initiation and progression of multiple organ failure that occurs in sepsis. Many natural active substances can be used to reduce the liver injury caused by sepsis. For this aim, the effects of myricetin and apigenin on mice model of acute liver injury was evaluated in this study.METHODS AND RESULTSThirty-six mice were randomly divided into six groups as; control, lipopolysaccharide (LPS) (5 mg/kg), LPS + myricetin (100 mg/kg), LPS + myricetin (200 mg/kg), LPS + apigenin (100 mg/kg), and LPS + apigenin (200 mg/kg) groups. Myricetin and apigenin were administered orally for 7 days, and LPS was administered intraperitoneally only on the 7th day of the study. 24 h after LPS application, all animals were sacrificed and serum biochemical parameters, histopathology and oxidative stress and inflammation markers of liver tissue were examined. Myricetin and apigenin pre-treatments increased serum albumin and total protein levels, liver GSH level and catalase and SOD activities and decreased serum ALT, AST, ALP, γ-GT, CRP, total and direct bilirubin levels, liver MPO activity, MDA, NOx, PGE₂, TNF-α, IL-1β, and IL-6 levels, iNOS and COX-2 mRNA levels, phosphorylation of NF-κB p65, IκB, and IKK proteins but not p38, ERK, and JNK proteins in LPS-treated mice. Myricetin and apigenin administration also regained the hepatic architecture disrupted during LPS application.CONCLUSIONMyricetin and apigenin pre-treatments led to reduction of liver injury indices and oxidative stress and inflammatory events and these flavonoids has probably hepatoprotective effects in acute liver injury.

100 项与 Liver(Esperion Therapeutics) 相关的药物交易

登录后查看更多信息